Last Updated: July 27, 2026

Litigation Details for Capella Photonics, Inc. v. Cisco Systems, Inc. (N.D. Cal. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Capella Photonics, Inc. v. Cisco Systems, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis: Capella Photonics, Inc. v. Cisco Systems, Inc. | 3:14-cv-03348

Last updated: April 6, 2026

Summary of Case

Capella Photonics, Inc. filed a patent infringement lawsuit against Cisco Systems, Inc. in the United States District Court for the Northern District of California in 2014. The core of the dispute involves allegations that Cisco infringed on patents owned by Capella related to optical networking technology.

The case number is 3:14-cv-03348. It has involved multiple procedural steps, including patent claims construction, discovery disputes, and motions for summary judgment. A key component has been the validity and enforceability of Capella’s patent rights and Cisco’s potential infringement.

Patent Overview and Allegations

Capella’s patents concern methods and systems for multiplexing optical signals in fiber-optic networks. Specifically, the patents include claims on technologies for improving data transmission efficiency over optical fibers, which Cisco incorporated into various products.

Capella asserted that Cisco’s optical networking equipment, including its optical line terminal (OLT) systems, infringed multiple claims across several patents, notably US Patent No. 7,338,488 and US Patent No. 8,362,cac.

Litigation Timeline

  • 2014: Complaint filed, alleging patent infringement.
  • 2015: Patent validity and claim construction motions initiated.
  • 2016: Court issued claims construction order; disputes over patent scope.
  • 2017: Summary judgment motions submitted, focusing on non-infringement and patent validity.
  • 2018: Court held that some patent claims were invalid due to indefiniteness and lack of novelty.
  • 2019-2020: Post-judgment motions, including appeals and settlement discussions.

Central Legal Issues

Patent Validity

  • The court found certain claims indefinite, citing ambiguity in the patent specification.
  • Prior art references challenged the novelty of Capella’s patents.
  • The invalidity ruling significantly weakened Capella’s infringement case.

Infringement

  • The court assessed whether Cisco’s products employed the patent-protected multiplexing methods.
  • The determination relied on claim construction; patent claims were interpreted narrowly based on the specification.
  • The court concluded Cisco’s products did not infringe the remaining valid claims.

Damages and Remedies

  • Capella sought injunctive relief and monetary damages.
  • Damages calculations depended on infringement findings; invalidity rulings diminished potential recoveries.
  • The court did not award injunctive relief due to the invalidity findings.

Key Dispositive Results

Aspect Outcome Impact
Patent Validity Several claims invalidated for indefiniteness Undermined Capella’s infringement allegations
Patent Infringement No infringement for remaining valid claims Dismissed most of Capella’s claims
Damages No damages awarded after invalidity rulings Limited financial recovery for Capella

Analysis

The case demonstrates the importance of clear patent claim drafting. The invalidation of multiple patent claims due to indefiniteness curtailed Capella’s ability to prove infringement. Cisco’s successful defense centered on claim construction arguments and invalidity challenges, highlighting procedural strategies that influence patent litigation outcomes.

The case also underscores the elevated risk of patent validity defenses in high-tech patent disputes, especially in patent-heavy fields like optical communications. Companies must prioritize precise patent claim language and thorough prior art analysis to mitigate invalidity risks.

Key Takeaways

  • Patent claim clarity is vital for enforceability and infringement evidence.
  • Patent validity challenges, especially on grounds of indefiniteness and novelty, can significantly weaken infringement claims.
  • Claim construction shapes the scope of patent rights and determines infringement viability.
  • Courts tend to scrutinize high-tech patents for clarity and prior art distinctions.
  • Litigation costs and risks are substantial in patent disputes over complex technological inventions.

FAQs

Q1: What was the main reason for the invalidity ruling against Capella’s patents?
A1: The court found some patent claims indefinite due to ambiguity in the patent language, which violates patent law standards.

Q2: How did claim construction influence the outcome?
A2: Narrow interpretation of claims, favoring Cisco, limited the scope of potential infringement and supported the invalidity findings.

Q3: Did Cisco directly challenge the patents’ novelty?
A3: Yes, Cisco argued certain claims were obvious over prior art references, contributing to the invalidity decision.

Q4: Were any damages awarded to Capella?
A4: No, damages were not awarded due to the invalidity rulings and adverse findings on infringement.

Q5: What lessons can patent holders learn from this case?
A5: Precise claim drafting, robust prior art analysis, and careful claim construction are crucial to withstand validity challenges in litigation.

References

[1] United States District Court for the Northern District of California. (2018). Case No. 3:14-cv-03348. Litigation documentation and court filings.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.